https://www.selleckchem.com/pr....oducts/5-cholesten-3
a variety of upper extremity conditions, including breast cancer survivors, are being evaluated in the clinic or research study. Despite a lack of evidence on all-important clinical measurement, two generic (DASH and WHODAS2) and two disease-specific (BCSQ-BC, Lymph-ICF) PROM demonstrated emerging evidence of adequate measurement properties. The stronger alignment of the BCSQ-BC to the breast cancer ICF core set makes it preferable is a disease-specific measure. The Lymph-ICF is recommended where lymphedema is a speci
Beğen
Yorum Yap
Paylaş
